Zoetis Inc. (NYSE:ZTS) Shares Acquired by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT raised its holdings in Zoetis Inc. (NYSE:ZTS) by 10.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 216,629 shares of the company’s stock after purchasing an additional 19,889 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Zoetis were worth $35,295,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Mizuho Securities USA LLC grew its holdings in Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the period. International Assets Investment Management LLC grew its stake in shares of Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after purchasing an additional 665,331 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares during the period. Finally, Holocene Advisors LP purchased a new stake in Zoetis during the third quarter worth about $110,809,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $157.38 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a market capitalization of $70.47 billion, a price-to-earnings ratio of 28.77, a PEG ratio of 2.77 and a beta of 0.90. The business has a 50-day moving average of $166.86 and a 200-day moving average of $178.14.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. Zoetis’s payout ratio is currently 36.56%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler cut their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $214.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.